Highly iodinated intravenous contrast material for PET/CT - a feasibility study

被引：7

作者：

不详

机构：

[1] Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital, Essen

[2] Department of Nuclear Medicine, University Hospital, Essen

[3] Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital, Essen, 45122 Essen

来源：

ROFO-FORTSCHRITTE AUF DEM GEBIET DER RONTGENSTRAHLEN UND DER BILDGEBENDEN VERFAHREN | 2008年 / 180卷 / 08期

关键词：

PET/CT; contrast medium; artifact; attenuation correction;

D O I：

10.1055/s-2008-1027520

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Purpose: Intravenous contrast materials (CM) are of benefit in PET/CT imaging. However, CM may influence tracer quantification and may cause artifacts when using the CT data for PET attenuation correction. The aim of the study was to assess the feasibility of applying a highly concentrated CM (HCCM, 400 mg iodine/ml) in PET/CT in comparison to a lower concentrated CM (LCCM, 300 mg iodine/ml). Materials and Methods: In 60 whole-body FDG PET/CT scans (30 scans each with HCCM and LCCM), tracer uptake (maximal standardized uptake value - SUVmax) and CT attenuation (Hounsfield Units) were quantified at 16 positions in different vessels and parenchyma. The number of potential PET artifacts was documented. The Mann-Whitney-Wilcoxon Test was performed for statistical assessment (p 0.05). Results: HCCM did not cause a significant increase in the SUVmax (p > 0.05) or the number of PET artifacts (p = 0.69) while simultaneously Significantly increasing CT attenuation (p = 0.002) as compared to LCCM in 11 / 16 positions. Conclusion: The application of HCCM seems feasible in PET/CT and should be considered in future protocols.

引用

页码：740 / 745

页数：6

共 32 条

[1]

Rodriguez-Vigil B., Gomez-Leon N., Pinilla I., Et al., PET/CT in lymphoma: Prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT, J Nucl Med, 47, pp. 1643-1648, (2006)

[2]

Beyer T., Antoch G., Muller S., Et al., Acquisition protocol considerations for combined PET/CT imaging, J Nucl Med, 45, (2004)

[3]

Antoch G., Freudenberg L.S., Beyer T., Et al., To enhance or not to enhance? 18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CT, J Nucl Med, 45, (2004)

[4]

Setty B.N., Sahani D.V., Ouellette-Piazzo K., Et al., Comparison of enhancement, image quality, cost, and adverse reactions using 2 different contrast medium concentrations for routine chest CT on 16-slice MDCT, J Comput Assist Tomogr, 30, pp. 818-822, (2006)

[5]

Awai K., Takada K., Onishi H., Et al., Aortic and hepatic enhancement and tumor-to-liver contrast: Analysis of the effect of different concentrations of contrast material at multi-detector row helical CT, Radiology, 224, pp. 757-763, (2002)

[6]

Furuta A., Ito K., Fujita T., Et al., Hepatic enhancement in multiphasic contrast-enhanced MDCT: Comparison of high- and low-iodine- concentration contrast medium in same patients with chronic liver disease, Am J Roentgenol, 183, pp. 157-162, (2004)

[7]

Rau M.M., Setty B.N., Blake M.A., Et al., Evaluation of renal transplant donors with 16-section multidetector CT angiography: Comparison of contrast media with low and high iodine concentrations, J Vasc Interv Radiol, 18, pp. 603-609, (2007)

[8]

Kinahan P.E., Townsend D.W., Beyer T., Et al., Attenuation correction for a combined 3D PET/CT scanner, Med Phys, 25, pp. 2046-2053, (1998)

[9]

Nakamoto Y., Chin B.B., Kraitchman D.L., Et al., Effects of nonionic intravenous contrast agents at PET/CT imaging: Phantom and canine studies, Radiology, 227, pp. 817-824, (2003)

[10]

Cohade C., Osman M., Nakamoto Y., Et al., Initial experience with oral contrast in PET/CT: Phantom and clinical studies, J Nucl Med, 44, pp. 412-416, (2003)

← 1 2 3 4 →